Sarepta highlights continued stability in muscular dystrophy study; Adimab grabs third tech transfer deal; Transcept rejects Retrophin buyout bid;

@FierceBiotech: Eli Lilly will eventually have to come to grips with the fact that its R&D strategy and execution has been woeful. Story | Follow @FierceBiotech

@JohnCFierce: IPO 2013 revival update: 37 biotechs out, $2.8B raised from IPOs. More on the way. Feature | Follow @JohnCFierce

@DamianFierce: Merged at last on KKR's dime, PRA and RPS say they're the world's fourth-largest CRO. Article from FierceCRO | Follow @DamianFierce

@EmilyMFierce: $25M NIH project will set up genomic variants database for clinical use. More from FierceBiotech Research | Follow @EmilyMFierce

> Cambridge, MA-based Sarepta Therapeutics ($SRPT) has come out with an update on its small study for the Duchenne muscular dystrophy drug eteplirsen. One cohort able to complete a 6-minute walking test demonstrated continued stability, with a decline in walking ability of less than 5% at 96 weeks of therapy. Eteplirsen's prospects were considerably enhanced with the high-profile Phase III blowup of a rival therapy from GlaxoSmithKline ($GSK) and Prosensa. Release

> Tillman Gerngross's Adimab has rolled out its third tech transfer deal of the year, this time with Novo Nordisk ($NVO). Within months Adimab expects to complete the rollout of its antibody technology to GlaxoSmithKline, Biogen Idec ($BIIB) and Novo Nordisk. Release

> Transcept Pharma ($TSPT) has rejected a $4 per share buyout offer from Retrophin, saying the price Martin Shkreli's biotech is willing to pay is too low. Transcept also licensed a migraine drug from Japan. Story

> Ampio Pharmaceuticals is raising $25 million. Story  

> Novartis ($NVS) has apologized to the Japanese public for data manipulation in its studies of Diovan, a blood pressure treatment. Story

> Once Perrigo is finished buying Elan ($ELN), the company expects to expand in the U.S. with new acquisitions. Story

Medical Device News

@FierceMedDev: EU committee backs tougher, U.S.-style device approval system. Article | Follow @FierceMedDev

@MarkHFierce: FierceDiagnostics has another great crop of stories. Check it out | Follow @MarkHFierce

@MichaelGFierce: Study: Artificial pancreas with inhaled insulin improves glucose control. Story from FierceDrugDelivery | Follow @MichaelGFierce

> Olympus looks to the future with launch of sinus surgery tool. More

> Medtronic takes Insulet's settlement in insulin pump patent spat. Story

> Klobuchar, Hatch: Not so fast on device tax repeal. Article

> Roche, Pacific Biosciences seal $75M clinical Dx partnership. Item

Pharma News

@FiercePharma: Another plant gets warning letter. This time in PR, on repeat labeling probs. Article from FiercePharmaManufacturing | Follow @FiercePharma

> Merck gives up on unsuccessful Januvia combo drug. Article

> Merck KGaA overhauls pharma management to boost growth. Story

Pharma Manufacturing News

@EricPFierce: Kashmir-born Ph.D. picked by FDA to head office in India where problems mount. Story | Follow @EricPFierce

> Pfizer dumping plant, 140 workers in Australia. Item

> Sanofi building its largest African plant in Algeria. Report

> Purdue building $59M plant in North Carolina. More

> J&J says more Doxil shortages imminent, tied to Ben Venue problems. Story

> FDA warning points to infrastructure issue in India. Article

Vaccines News

> Merck KGaA lung cancer vaccine to re-enter Phase III. Item

> GSK, Merck and Pfizer join JP Morgan vaccine investment fund. Report

> European prices reapply old pressures to vaccine makers. Story

> Pandemic leads researchers to universal flu vaccine 'blueprint.' More

> U.K. gov makes U-turn on link between GSK vaccine and narcolepsy. Article

And Finally... Chinese researchers, along with Swiss and South Korean institutes, are developing magnetic nanobots to carry drugs to the brain. Item

Suggested Articles

The ambitious target is enabled by an AI discovery platform that Healx thinks gives it a scalability that has more in common with tech than biotech.

Eli Lilly is closing down its U.K.-based Erl Wood neuroscience in Surrey, leading to cuts and relocations.

After being hailed as a near mystic when it came to stock picks, Britain’s once great oak has been cut down to a sapling as Neil Woodford gets the ax.